



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/043,933	03/30/1998	JEAN-MARC BALLOUL	017753-094	7553
21839	7590	06/29/2004	EXAMINER	
BURNS DOANE SWECKER & MATHIS L L P			FOLEY, SHANON A	
POST OFFICE BOX 1404				
ALEXANDRIA, VA 22313-1404			ART UNIT	PAPER NUMBER
			1648	

DATE MAILED: 06/29/2004

Please find below and/or attached an Office communication concerning this application or proceeding.



UNITED STATES DEPARTMENT OF COMMERCE
U.S. Patent and Trademark Office

Address : COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450

APPLICATION NO./ CONTROL NO.09/043933	FILING DATE 3/30/1998	FIRST NAMED INVENTOR / Jean-Marc Balloul PATENT IN REEXAMINATION	ATTORNEY DOCKET NO. 017753-094
--	--------------------------	---	-----------------------------------

EXAMINER

Shanon Foley

ART UNIT	PAPER
----------	-------

1648

6254

DATE MAILED:

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner for Patents

The reply filed on April 2, 2004 is not fully responsive to the prior Office Action because of the following omission(s) or matter(s):

The independent claims not previously withdrawn from consideration due to a non-elected invention and by original presentation, i.e. claims 89, 105, 107, 117 and 118, have been amended to state that the proteins are expressed from independent expression control elements. As explained on page 2 of the Office action mailed June 5, 2002, this limitation encompasses expression from an expression vector, which was the subject matter of Group II in the restriction requirement mailed May 7, 1999. Applicant elected group I in the instant application in the amendment submitted June 7, 1999, which is drawn to a pharmaceutical composition comprising early and late proteins of the papillomavirus. As the claims are currently amended in the instant case, there is no distinction between administering the papillomavirus polypeptides in an expression vector from independent expression control elements and administering an expression vector expressing papillomavirus polypeptides from independent expression control elements, which is the subject matter of non-elected group II. Applicant is required to amend the instant claims so that the subject matter examined remains consonant with the elected invention.

See 37 CFR 1.111. Since the above-mentioned reply appears to be *bona fide*, applicant is given **ONE (1) MONTH or THIRTY (30) DAYS** from the mailing date of this notice, whichever is longer, within which to supply the omission or correction in order to avoid abandonment. EXTENSIONS OF THIS TIME PERIOD MAY BE GRANTED UNDER 37 CFR 1.136(a).

Shanon Foley
Patent Examiner, 1648